Kalderos, a data infrastructure and analytics company, has released its annual report highlighting the costs of systemic challenges in drug discount programs and their impact on all stakeholders. The report outlines a new paradigm of cooperation among drug discount program stakeholders that benefits everyone, particularly patients. The Medicaid Drug Rebate Program (MDRP), 340B Drug Pricing Program, and other similar programs are expanding, leading to an increase in the volume and cost of inaccurate drug discount claims. Kalderos' MDRP Discount Monitoring solution analyzes and validates claims data while flagging potential duplicate discounts and other inaccurate claims. Between 2016 and Q1 2023, the platform identified nearly $1 billion in inaccurate discount requests. Costs of inaccurate discount payments include mounting administrative responsibilities for manufacturers and covered entities that can redirect valuable resources away from patients. To date, thousands of 340B covered entities have used Kalderos’ Discount Hub solution to participate in the good faith inquiry process and resolve concerns related to duplicate discounts.
The healthcare industry is facing significant challenges due to inaccuracies in drug discount claims that result in overpayments by drug manufacturers. Inaccurate payments also lead to mounting administrative responsibilities for manufacturers and covered entities that can redirect valuable resources away from patients. Kalderos' MDRP Discount Monitoring